A detailed history of Andra Ap Fonden transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Andra Ap Fonden holds 12,700 shares of ALNY stock, worth $3.09 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
12,700
Previous 3,100 309.68%
Holding current value
$3.09 Million
Previous $753,000 363.88%
% of portfolio
0.05%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$233.81 - $287.01 $2.24 Million - $2.76 Million
9,600 Added 309.68%
12,700 $3.49 Million
Q2 2024

Aug 07, 2024

BUY
$143.31 - $247.0 $444,261 - $765,700
3,100 New
3,100 $753,000
Q4 2023

Feb 15, 2024

BUY
$151.41 - $196.57 $151,410 - $196,570
1,000 Added 2.9%
35,500 $6.8 Million
Q3 2023

Nov 09, 2023

SELL
$170.77 - $211.65 $1.02 Million - $1.27 Million
-6,000 Reduced 14.81%
34,500 $6.11 Million
Q2 2023

Aug 09, 2023

SELL
$185.01 - $212.05 $869,547 - $996,635
-4,700 Reduced 10.4%
40,500 $7.69 Million
Q1 2023

May 12, 2023

SELL
$182.66 - $235.53 $1.9 Million - $2.45 Million
-10,400 Reduced 18.71%
45,200 $9.05 Million
Q4 2022

Feb 13, 2023

BUY
$185.53 - $241.31 $1.3 Million - $1.69 Million
7,000 Added 14.4%
55,600 $13.2 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $900,510 - $1.51 Million
6,500 Added 15.44%
48,600 $9.73 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $1.65 Million - $2.32 Million
13,700 Added 48.24%
42,100 $6.14 Million
Q4 2021

Feb 15, 2022

BUY
$159.56 - $209.29 $1.36 Million - $1.78 Million
8,500 Added 42.71%
28,400 $4.82 Million
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $424,375 - $519,325
2,500 Added 14.37%
19,900 $3.76 Million
Q2 2021

Aug 16, 2021

BUY
$128.63 - $176.89 $180,082 - $247,645
1,400 Added 8.75%
17,400 $2.95 Million
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $317,075 - $439,225
-2,500 Reduced 13.51%
16,000 $2.26 Million
Q4 2020

Feb 12, 2021

BUY
$122.97 - $147.0 $528,771 - $632,100
4,300 Added 30.28%
18,500 $2.4 Million
Q3 2020

Nov 12, 2020

SELL
$121.19 - $165.49 $2.9 Million - $3.96 Million
-23,900 Reduced 62.73%
14,200 $2.07 Million
Q2 2020

Aug 06, 2020

BUY
$104.21 - $156.44 $385,577 - $578,828
3,700 Added 10.76%
38,100 $5.64 Million
Q1 2020

May 13, 2020

BUY
$93.12 - $133.99 $1.86 Million - $2.68 Million
20,000 Added 138.89%
34,400 $3.74 Million
Q4 2019

Feb 10, 2020

BUY
$74.51 - $124.23 $864,316 - $1.44 Million
11,600 Added 414.29%
14,400 $1.66 Million
Q3 2019

Nov 19, 2019

BUY
$70.9 - $87.82 $198,520 - $245,895
2,800 New
2,800 $225,000
Q2 2019

Aug 15, 2019

SELL
$65.86 - $92.79 $368,816 - $519,624
-5,600 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$72.76 - $93.45 $407,456 - $523,320
5,600 New
5,600 $523,000
Q3 2018

Oct 16, 2018

SELL
$87.52 - $122.67 $1.12 Million - $1.57 Million
-12,800 Closed
0 $0
Q2 2018

Aug 17, 2018

SELL
$88.31 - $107.8 $167,789 - $204,820
-1,900 Reduced 12.93%
12,800 $1.26 Million
Q1 2018

Apr 10, 2018

BUY
$115.92 - $148.54 $1.48 Million - $1.9 Million
12,800 Added 673.68%
14,700 $1.75 Million
Q4 2017

Feb 14, 2018

BUY
$114.49 - $139.98 $217,531 - $265,962
1,900
1,900 $241,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Andra Ap Fonden Portfolio

Follow Andra Ap Fonden and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Andra Ap Fonden, based on Form 13F filings with the SEC.

News

Stay updated on Andra Ap Fonden with notifications on news.